<DOC>
	<DOC>NCT02027961</DOC>
	<brief_summary>The purpose of this study is to determine the maximum tolerated dose and the safety profile of MEDI4736 in combination with dabrafenib and trametinib or with trametinib alone in subjects with metastatic or unresectable melanoma with BRAF-mutation positive or Wild Type BRAF, respectively.</brief_summary>
	<brief_title>Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Adults &gt;/= 18 years old Histologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable) or Stage IV (metastatic) and determined to be BRAF V600E or V600K mutationpositive (cohort A) or mutationnegative (cohorts B and C) ECOG performance status of 0 or 1 Measurable disease by radiographic or physical examination Adequate organ and marrow function Willingness to provide consent for biopsies positive or BRAF WT measurable disease, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate organ and marrow function Prior treatment with a BRAF inhibitor or MEK inhibitor Any prior Grade ≥ 3 immunerelated adverse event while receiving immunotherapy Active or prior documented autoimmune disease within the past 2 years History of or current risk for retinal vein occlusion (RVO) or central serous retinopathy (CSR) History of or current cardiovascular risk including myocardial infarction, ≥ Class II congestive heart failure, uncontrolled arrhythmias, or refractory hypertension Active, untreated CNS metastases Women who are pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic or Unresectable Melanoma, MEDI4736, dafrafenib, trametinib, BRAF-mutation positive, wild-type BRAF, PD-L1, PD-1</keyword>
</DOC>